Introducing Fierce Biotech’s 2023 Fierce 15 – FOG and RayzeBio
It’s been a tough year for biotech, so how about a little good news? In between all the layoffs, restructurings and last-ditch strategic option hunting, we wanted to take a moment to shine a spotlight on 15 innovative and truly fierce biotechs. Everyone we talk to in the Fierce Biotech universe tells us that science […]
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
SAN DIEGO, August 16, 2023 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AlloNK® (also known as AB-101), in combination with rituximab […]
ImmPACT Bio Announces FDA Clearance of IND Application
Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma West Hills, Calif., August 15, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) […]
